Evaluation Of Treatment Response According To Clinical Prognostic Factors Of Diffuse Large B Cell Non-Hodgkin Lymphoma | ||
| Al-Azhar International Medical Journal | ||
| Volume 2023, Issue 1, January 2023 | ||
| DOI: 10.58675/2682-339X.2123 | ||
| Authors | ||
| Mohsen Salah El-Din Zikry; Eslam Mohamed Mohamed; Mohamed Ahmed Eid Moustafa | ||
| Department of Clinical Oncology, Faculty of Medicine for boys, Al-Azhar University, Cairo, Egypt. | ||
| Abstract | ||
| Background: Non-Hodgkin lymphomas (NHL) are heterogeneous neoplasms of the lymphoid tissues variously derived from B cell, T cell, natural killer cell. In Egypt, NHL represent 4.64 % of all cancer. NHL is the fifth most frequent malignancy. Aim and objectives: to evaluate the Treatment Response According to Clinical Prognostic Factors Of Diffuse Large B Cell Non-Hodgkin Lymphoma. Subjects and methods: This study was a retrospective analysis of sixty individuals diagnosed with diffuse large B cell non-Hodgkin's lymphoma (DLBCL) and treated at El Hussein hospital's Clinical Oncology Department, Faculty of Medicine El Azhar University throughout the period among Junuary 2015 to Octobar 2022. Result: about 81.7 % of study was more than 60 years the majority of patients were male patients. the commonest site of extra-nodal involvement was spleen patients followed by BM patients. The most common presenting symptoms was painless swelling in patients. As regards mortality rate distribution, it found that (31.7%) 19/60 patients died and (68.3%) 41/60 patients were alive and disease free on last visit. there was a difference that may be considered statistically significant among the studied groups regarding OS among DLBCL cases who received CHOP regimen according to PS subgroups. Conclusion: the current study showed that the dosage intensity of cyclophosphamide and doxorubicin will play an essential role in the treatment regimen plan for DLBCL in the future, particularly in patients at greater risk. Complete response (CR) was higher in males who had normal LDH, had good PS, presented with early stages and lower IPI risk, the intensity of the dosage of doxorubicin and cyclophosphamide had a substantial impact on the CR rate. | ||
|
Statistics Article View: 33 |
||
